Recognize Yourself?
Role: Cell Therapy Developer
Your Goals:
-
Access reliable clinical-grade materials for translational and clinical programs
-
Use validated and reproducible gene-editing platforms
-
Move efficiently from research to clinical manufacturing readiness
Your Challenges:
-
Fragmented workflows across multiple suppliers and service providers
-
Uncertainty around regulatory compliance and documentation requirements
-
Variability in donor cell sourcing affecting consistency and comparability
Your Motivations:
-
Predictable, high-quality results you can trust
-
Faster project timelines without compromising scientific rigor
-
Streamlined end-to-end solutions that simplify translational development
Scientific Complexity
Cell and gene therapy development is inherently complex and difficult to scale. Variability in cell behavior, reprogramming efficiency, and heterogeneity hinder reproducible clinical-grade production.
REPROCELL's StemRNA Clinical Reprogramming Technology reduces variability to support more consistent iPSC generation.
Regulatory Uncertainty
Evolving global guidelines from organizations like FDA, EMA, PMDA create complexity, in ensuring consistent GMP compliance across regions.
REPROCELL's processes align with thes eregulatory frameworks and are supported by a US FDA Drug Master File (DMF) and an experienced QA team.
Cost, Materials & Timeline Pressure
High manufacturing costs, reagent variability and complex workflows, increase the risk of delays.
REPROCELL's RNA reprogramming technology, curated reagent portfolio and highly experienced teams optimize processes before committing to MCB generation.
Workflow Fragmentation
Multiple vendors and complex workflows create inconsistencies in quality, traceability, and accountability.
REPROCELL provides a single-source solution for Clinical Stem Cell services, from donor qualification to MCB generation and characterization, with one point of contact throughout the project.
Trusted by Leading Cell Therapy Innovators – Case Study
StemRNA™ Clinical iPSC Seed Clone Supports Fertilo Development – U.S. Phase 3 Fertility Therapy
Gameto needed a reliable clinical-grade iPSC starting material to generate ovarian support cells for its Fertilo therapy. Without a consistent, well-characterized cell source, producing reproducible cells for clinical manufacturing and advancing the therapy into trials would be challenging.
Gameto used REPROCELL’s Gameto used REPROCELL’s StemRNA™ Clinical Seed Clone VCT-37-F35, produced using REPROCELL’s StemRNA™ Clinical Reprogramming Technology, to establish a stable iPSC foundation for its program. This enabled consistent production of ovarian support cells that mature eggs outside the body, helping advance Fertilo into U.S. Phase 3 clinical trials and supporting the first live birth using the technology.
Image courtesy of Gameto
Regenerative Medicine Pipeline
REPROCELL is advancing the development of a wide range of therapies using stem cells and immune cells, with the aim of enabling next-generation, patient-tailored medicine.
Our current pipeline includes the adipose-derived mesenchymal stem cell product Stemchymal® for spinocerebellar degeneration; iPSC-derived neural glial progenitor cells (iGRP) targeting central nervous system disorders such as ALS and TM; and tumor-infiltrating lymphocyte (TIL) therapy and Glypican-1 CAR-T therapy as cell-based cancer immunotherapies.
Through the development of these therapies, REPROCELL is committed to accelerating the translation of innovative treatments into clinical practice.
